Sotac Pharmaceuticals Limited, part of the SOTAC Group in Gujarat, is a pharmaceutical company specializing in contract manufacturing and loan licensing of a diverse range of pharmaceutical products. Originally formed as a partnership in 2015, it transitioned to a public limited company by 2022. The company manufactures Non Beta-Lactam and Beta-Lactam tablets and capsules, oral liquids, dry syrups, and external preparations like nasal and relief sprays. Its therapeutic portfolio spans Anti-Diabetic, Anti-Psychotic, Vitamins, Anti-Cold, Cardiac, and various other treatments, catering to a wide spectrum of companies for formulation and production needs.
In 2017, Sotac Pharmaceuticals began manufacturing with a significant capacity, and in 2022, expanded its reach by acquiring major stakes in SOTAC Healthcare and SOTAC Research. Additionally, it initiated SOTAC Lifescience, holding a 51% stake. The company plans an Initial Public Offering (IPO) of up to 3 million equity shares, indicating a strategic move to expand its market presence and capital base.
